Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MLNR | O43193 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320206 | 0.79 | L3MBTL1 (0.46) | L3MBTL1LIPEMAPTLMNA | |
| SCHEMBL3342716 | 0.78 | GPR119 (0.66) | GPR119 | |
| SCHEMBL3320665 | 0.78 | HRH2 (0.47) | L3MBTL1KMT2ALIPEGPR119POLB | |
| SCHEMBL13361619 | 0.78 | HRH2 (0.47) | L3MBTL1KMT2ALIPEGPR119POLB | |
| SCHEMBL3348834 | 0.77 | EPHX2 (0.48) | KMT2ALMNA | |
| SCHEMBL26644531 | 0.72 | HRH3 (0.58) | — | |
| SCHEMBL3342725 | 0.72 | GPR119 (0.61) | GPR119 | |
| SCHEMBL3320075 | 0.72 | POLB (0.62) | KMT2APOLBLMNA | |
| SCHEMBL6135696 | 0.71 | ALDH1A1 (0.62) | L3MBTL1KMT2A | |
| SCHEMBL3342770 | 0.71 | GPR119 (0.59) | GPR119LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| EP-1202968-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010834-A9 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | L3MBTL1 2349/4885KMT2A 3765/4885LIPE 3768/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | L3MBTL1 1972/4885KMT2A 3725/4885LIPE 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.